Conference Track

HIV Management in Women

Source: CCO Official Conference Coverage of the 2008 International AIDS Conference

Capsule Summaries

Nearly One Half of HIV-Infected Women Wish and Intend to Have Children, but MTCT Knowledge Often Inaccurate
CASTLE Subanalysis: Once-Daily Atazanavir/Ritonavir and Twice-Daily Lopinavir/Ritonavir as Initial Therapy Equally Safe and Effective in Men and Women
ARTEMIS: First-Line Darunavir/Ritonavir Effective and Well Tolerated Irrespective of Sex, Age, or Race
Similar Efficacy Demonstrated in HIV-Infected Men vs Women Receiving Once-Daily or Twice-Daily Lopinavir/Ritonavir
No Increased Risk of Birth Defects With Prenatal Lopinavir/Ritonavir Exposure Found in Antiretroviral Pregnancy Registry
Atazanavir/Ritonavir Effective and Safe Regimen for Pregnant Women: Dose Increases Recommended Due to Low Plasma Drug Concentrations During Third Trimester
Resistance Mutations Detected in 1 in 10 Antiretroviral-Naive Brazilian Women Ceasing Prophylactic HAART at Delivery
GRACE Study: Safety, Efficacy of Darunavir/Ritonavir in Racially Diverse, Antiretroviral-Experienced Women
General, Medical Communities Need Education About Pregnancy, Child-Bearing by HIV-Infected Women, Survey Reveals
Inadequate Reproductive Counseling for HIV-Infected Women Who Are or Want to Become Pregnant Revealed by Survey
Workshop-Based HIV/STI Intervention Reduces Incidence of Nonviral STIs, HPV Among Young, Black American Women
WIHS: Progestin-Only Contraception Associated With Insulin, Cholesterol Abnormalities in HIV-Infected Women and Those at Risk of Infection

Expert Analysis

HIV Management in Women

Faculty:

Judith S. Currier, MD, MSc
Sally Hodder, MD
Kathleen E. Squires, MD

Learning Objectives

Upon completion of this activity, participants should be able to:

Summarize data concerning the prevalence of HIV infection among women throughout the United States and the world
Discuss issues concerning reproduction and contraception among HIV-infected women
Explain efficacy results and adverse events related to the sex of participants from clinical trials with antiretrovirals

CME CREDIT INFORMATION

Release Date: 10/06/08

Expiration Date: 10/05/09

Physicians: maximum of 1.25 AMA PRA Category 1 Credits™

Registered Nurses: 1.6 Nursing CE credits

Pharmacists: 1.3 contact hours (0.13 CEUs)

Status: Please log in to view status

Disclaimer: The materials published on the Clinical Care Options Web site reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.